SageView Advisory Group LLC Grows Position in Johnson & Johnson $JNJ

SageView Advisory Group LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 38.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,164 shares of the company’s stock after purchasing an additional 8,453 shares during the period. SageView Advisory Group LLC’s holdings in Johnson & Johnson were worth $5,593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $26,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter worth about $28,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. increased its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc raised its stake in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, March 5th. Barclays raised their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. Bank of America reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Wells Fargo & Company raised their price target on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $234.87.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approvals bolster commercial and clinical growth runway for oncology/immunotherapy — the TECVAYLI (teclistamab) + DARZALEX FASPRO approval opens a newer immune‑engaging combo for relapsed/refractory multiple myeloma that could shift treatment into earlier lines and meaningfully increase oncology sales upside. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU label expansion for Akeega (prostate cancer) increases market opportunity in BRCA‑mutated metastatic hormone‑sensitive prostate cancer — supports future oncology revenue and pipeline leverage in targeted therapies. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Company presentation / transcript at Barclays healthcare conference provides management color on strategy/execution; useful for analysts but contains no surprise guidance that would immediately change valuations. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/coverage pieces and valuation reviews have brought JNJ back onto investor radars after recent rallies; helpful context for longer‑term positioning but not an immediate catalyst. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Neutral Sentiment: Industry/competitive articles (e.g., on Hologic) highlight device market dynamics that could inform med‑tech positioning; monitor for share gains/losses in specific device categories. What Drives Hologic’s GYN Surgical Strength in a Competitive Market?
• Negative Sentiment: Short interest rose ~20.8% in February (to ~25.1M shares), increasing bearish positioning — could add downward pressure if momentum reverses or sentiment worsens. (internal short‑interest report)
• Negative Sentiment: Two J&J units agreed to pay $65M to settle a Tracleer antitrust class action — a modest cash impact but a headline legal item that slightly offsets positive regulatory news. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Stock Up 0.5%

NYSE JNJ opened at $243.75 on Wednesday. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The company has a market capitalization of $587.41 billion, a P/E ratio of 22.06, a P/E/G ratio of 2.40 and a beta of 0.34. The stock has a 50 day moving average price of $229.80 and a 200-day moving average price of $205.27. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.